Chicago Mercantile Exchange (CME): New follow here. Looking REAL good since...

New follow here. Looking REAL good since the

CashCowMoo · 2025-03-18T03:40:33.7270000Z

New follow here. Looking REAL good since the start of 2025!

Play Episode

7min

Proactive - Interviews for investors

Genflow Biosciences CEO welcomes new investment; outlines dog longevity trial

Genflow Biosciences PLC CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about a pivotal new direction for the company as it initiates a clinical trial focused on improving aging in dogs. Leire described the trial as a natural evolution from Genflow's previous success in mice, noting the commercial appeal of the canine market. “There is nothing to improve really the quality of life of our aging dogs,” he said, adding that the study meets a significant unmet need. The trial will run for one year, with six months of treatment followed by six months of assessment. It's being managed by independent contract research organisation Syngene. Leire emphasised the scientific rigour of the trial, which is controlled, randomised and includes both aesthetic and biological endpoints. These include coat quality, mitochondrial function, and methylation clocks — all of which have potential crossover value for human applications. Leire also highlighted the company’s differentiated approach compared to US competitors using repurposed drugs like metformin. Genflow, he said, is pursuing gene therapy with the potential for greater impact. The investment supporting the trial, although limited in size, is seen as a strategic vote of confidence, bringing in credible investors from outside the UK, including the US. Leire described the initiative as a major step that could generate near-term revenue and redefine the company’s biotech positioning. For more company updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future content. #GenflowBiosciences #GeneTherapy #DogAging #BiotechInvestment #LongevityResearch #Mitochondria #PetHealth #ClinicalTrials #AgingDogs #BiotechNews

Proactive - Interviews for investors

Biome Australia expands global footprint, targets strong growth in clinically proven Probiotics

Biome Australia Managing Director Blair Norfolk joined Steve Darling from Proactive to talk about the company’s expansion strategy and continued growth in clinically validated, condition-specific probiotics. As a leader in live biotherapeutics, Biome Australia has developed probiotics with proven benefits across various health conditions, including mental health, asthma, cardiovascular health, and skin care. The company has over 20 clinical trials validating its products in those areas including the world’s first asthma probiotic, which achieved a 64% reduction in asthma events. Biome’s practitioner-only model ensures that products are recommended by health professionals and sold behind pharmacy counters, contributing to approximately 30% of total sales. While Australia remains the core market, generating over 90% of revenue, Biome is actively expanding into New Zealand, the UK, Ireland, and Canada. Norfolk noted that early results in Canada are ahead of schedule, with further updates expected on the ASX. Instead of launching new products, Biome is focused on expanding use cases for its existing 18-product portfolio, ensuring efficient cash flow management and lower product risk. Biome has emerged as the #2 probiotics brand in Australia’s community pharmacy market by total revenue. Norfolk credited ongoing research and innovation as key drivers of success. Looking ahead, Biome expects a strong close to FY25, fueled by increased demand during cold and flu season, and is on track to deliver its first full-year net profit as part of its Vision 27 strategic plan. #proactiveinvestors #biomeaustralialimited #asx #bio #BlairNorfolk #LiveBiotherapeutics #MentalHealthProbiotics #AsthmaTreatment #PharmaceuticalGrowth #ASXUpdates #NaturalMedicine #TargetedTherapy #PharmacyInnovation #InvestingInHealth #CanadianPharma #ColdAndFluSeason

Proactive - Interviews for investors

Chesnara CEO discusses strong 2024 results, dividend growth and M&A outlook

Chesnara PLC (LSE:CSN) CEO Steve Murray talked to Proactive's Stephen Gunnion about the company’s strong 2024 full-year results, highlighting robust cash generation and consistent dividend growth. Murray highlighted that Chesnara generated £60 million in cash over the year, providing strong dividend coverage and supporting its 20-year track record of uninterrupted dividend growth. The business also increased its overall value and maintained a strong solvency position. The interview also covered Chesnara’s acquisition strategy, with Murray detailing the second Canada Life deal, which delivered an uplift in economic value to £11 million—higher than the £8 million initially expected—off a £2 million consideration. He explained that Chesnara currently holds around £200 million in acquisition firepower, supported by a solvency capital ratio of 203%. Murray described the current M&A pipeline as “positive,” noting that a reduction in private equity competition is opening up new opportunities in the UK and Benelux. He also commented on broader macroeconomic conditions, noting that despite some volatility, Chesnara’s long-term outlook remains stable due to natural hedges and long-duration contracts. Looking ahead to 2025, Murray reiterated Chesnara’s confidence in maintaining dividend growth, underpinned by strong visibility on future cash flows well above required commitments. For more CEO interviews and investor insights, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to our channel, and hit the notification bell so you never miss an update. #Chesnara #InsuranceStocks #DividendGrowth #MergersAndAcquisitions #CashGeneration #UKStocks #BeneluxMarkets #CanadaLifeDeal #FinancialResults #InvestorUpdates #ProactiveInvestors

Proactive - Interviews for investors

Atrato Partners on Social Housing REIT (SOHO): strategy, debt and dividend outlook

Atrato Partners, the newly appointed Investment Manager of Social Housing REIT (SOHO) talked with Proactive's Stephen Gunnion about the current state of the specialised supported housing sector and how the company is tackling key challenges within its portfolio. Fund manager Adrian D'Enrico was joined by Michael Carey and Natalie Markham, offering a comprehensive update on SOHO’s operational and financial performance. D'Enrico addressed common misconceptions about the sector, clarifying that it is not temporary or homeless accommodation, but instead provides long-term homes for adults with care needs. “A misconception as well is that specialised supported housing is a passive investment based on the long lease,” he explained, underlining the importance of resident occupancy and the operational real estate nature of the assets. Carey detailed the steps taken to resolve issues with Parasol and My Space Housing Solutions, including lease transfers to stronger providers, which are expected to improve rent collection. “We’ve collected 72% of the contracted amount so far with Westmoreland, and we’re confident we’ll meet our target,” he said. Markham reviewed the FY24 results, noting that while net tangible assets declined to £0.99 per share, rent collection stood at 93% and the company maintains strong debt metrics with an average maturity of 8.6 years and a 2.74% all-in cost. For more updates like this, head to Proactive's YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss future content. #SocialHousing #REIT #AtratoPartners #SOHO #SpecialisedSupportedHousing #IncomeSecurity #RealEstateInvestment #DividendStocks #UKHousing #InvestorUpdate #PropertyPortfolio #ESGInvesting

Followers	114
Posts	13657
Boards Moderated	0
Alias Born	05/27/2004

Volume:	102
Day Range:
Bid:	263.70
Ask:	265.29
Last Trade Time:	7:37:46 AM EDT
Total Trades:	56

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

CME Detailed Quote

Recent CME News

More CME News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent CME News

Go Ad-Free